In a pooled analysis study of four Asian clinical trials on anti‐PD‐1 monotherapy, advanced melanoma with NRAS mutations had lower response rate and poorer prognosis, especially in acral and mucosal subtypes.14 Here, RPL17 is linked to melanoma.